RxDoctor Payments Data

Sarah Silvers, NP

Nurse Practitioner · Wilmington, NCNPI 1144959529

Payments from drug & device makers

$904in general payments, 2019–2025

Across 42 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$508
  • Philips North America LLC$106
  • Johnson & Johnson$101
  • Vertex$68
  • Amgen$40
  • Recor Medical Inc$25
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$904 in reported general payments places this provider in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$60,398
Medicare patients
440
Services billed
1,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$54,989
FarxigaDapagliflozin Propanediol24$28,984
EntrestoSacubitril/Valsartan19$19,245
Repatha SureclickEvolocumab17$12,844
BrilintaTicagrelor21$12,527
Nebivolol Hcl46$2,660
Telmisartan72$2,594
Metoprolol Succinate184$2,424
Rosuvastatin Calcium80$1,672
Amlodipine Besylate111$1,068
ClopidogrelClopidogrel Bisulfate111$959
Losartan Potassium101$737
Nitroglycerin62$664
Atorvastatin Calcium85$659
Carvedilol40$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$22$41,51145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →